Abstract: The disclosure relates to a new crystalline form of genistein. The disclosed crystalline form is crystalline genistein sodium salt dihydrate. The disclosure also relates to the novel genistein salt composition represented by this crystalline form. Therapeutic compositions containing crystalline genistein sodium salt and a pharmaceutically acceptable carrier are described. The disclosure also relates to therapeutic methods comprising the step of administering to a patient in need thereof a therapeutically effective amount of a therapeutic composition containing the crystalline form of the disclosure or crystalline genistein sodium salt dihydrate.

Abstract: A method and apparatus for performing a radiation scan of a structure involve arranging a source of penetrating radiation and a radiation detector at opposed ends of a radiation path through the structure, oriented in such a way that the source emits radiation along the path through the structure and the detector is capable of detecting the radiation after it has passed through the structure and monitoring the radiation emitted from the source that is detected by the detector. At least one continuous loop of a cable is mounted on the structure between at least two fixed locations on the structure so that the cable is movable along its length relative to the structure, and the at least one of the source of penetrating radiation and the radiation detector are fixed to the cable.

Abstract: The invention relates to a method, composition and inhaler system for treatment or prophylaxis of influenza infection in one or more subjects by applying to a surface selected from air filters, sick room surfaces and respiratory mucosal membranes at least one immune material selected from antibodies and fragments thereof which bind a least one Influenza A antigen selected from the group consisting of H1, H3 and H5, the immune material being derived from hyperimmune milk products such as hyperimmune colostrum said hyperimmune milk products being prepared by inoculation of mammals with antigen composed of a least one Influenza A antigen selected from H1, H3 and H5.

Abstract: The disclosure relates to a new crystalline form of genistein. The disclosed crystalline form is crystalline genistein sodium salt dihydrate. The disclosure also relates to the novel genistein salt composition represented by this crystalline form. Therapeutic compositions containing crystalline genistein sodium salt and a pharmaceutically acceptable carrier are described. The disclosure also relates to therapeutic methods comprising the step of administering to a patient in need thereof a therapeutically effective amount of a therapeutic composition containing the crystalline form of the disclosure or crystalline genistein sodium salt dihydrate.

Abstract: The present invention relates to prodrugs of a class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of prodrugs of HIV aspartyl protease inhibitors characterized by favorable aqueous solubility, high oral bioavailability and facile in vivo generation of the active ingredient. This invention also relates to pharmaceutical compositions comprising these prodrugs. The prodrugs and pharmaceutical compositions of this invention are particularly well suited for decreasing the pill burden and increasing patient compliance. This invention also relates to methods of treating mammals with these prodrugs and pharmaceutical compositions.

Abstract: A method for prophylaxis of infection of the respiratory tract of a subject by pathogenic airborne bacteria the method comprising administering to the subject by inhalation binding proteins directed against the bacteria. the pathogenic bacteria is a bacteria which survives inside phagocytes and the binding proteins are directed against said bacteria which survives inside phagocytes. The binding proteins comprise antibodies or antibody fragments directed against said bacteria which survives inside phagocytes. The binding proteins are selected from the group consisting of polyclonal antibodies, monoclonal antibodies, F(ab) fragments, F(ab?)2 fragments, antibody tip fragments, chimeric and humanized antibodies and fragments and recombinant antibodies and fragments.

Abstract: A digital palette and a digital pen device are used to create or manipulate a digital document to provide complex information using features, such as graphical features selected from stencils, shapes, and connectors and possibly to apply one or more attributes to the digital document. The digital palette may have a custom layout. The features on the digital palette may be selected from a variety of sources, such as digital stencil libraries. The digital palette and digital document may be arranged on the same or different sheets of digital paper overlying one or more digital patterns. Information communicated from the digital palette to the digital document may be uploaded, processed, reviewed, changed and stored in a computer. Lastly, the digital document may be finalized and printed to incorporate all changes previously made using the digital palette, the digital pen device and the computer.

Abstract: The present invention relates to prodrugs of a class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of prodrugs of HIV aspartyl protease inhibitors characterized by favorable aqueous solubility, high oral bioavailability and facile in vivo generation of the active ingredient. This invention also relates to pharmaceutical compositions comprising these prodrugs. The prodrugs and pharmaceutical compositions of this invention are particularly well suited for decreasing the pill burden and increasing patient compliance. This invention also relates to methods of treating mammals with these prodrugs and pharmaceutical compositions.

Abstract: This invention relates to a bioactive composition comprising: (d) pH sensitive bioactive agent (e) an edible carboxylic acid containing moiety and (f) an edible alkalising moiety, wherein the proportion of said moieties and active agent provide pH control such that (i) when 400 mg of said composition is added to 20 ml of 0.033 normal hydrochloric acid and at a temperature of 37+/?3° C., the pH reaches a value in the range 4 to 8, and (ii) when 400 mg of said composition is added to 20 ml of deionised water at pH 7 and at a temperature of 37+/?3° C., the pH reaches a value less than 8.5.

Abstract: A digital paper-enabled system includes a spreadsheet printed on digital paper and usable with a digital writing instrument, such as a digital pen. A method of using the system includes (1) designing a digital paper-enabled spreadsheet with a spreadsheet integration module; (2) printing the designed spreadsheet to receive writing from a digital pen (3) uploading data from the digital pen to a processing system; (4) reviewing the uploaded data using a display device associated with the processing system; and (5) storing the uploaded data, which may include exporting one or more portions of the uploaded data to another display or processing system.

Abstract: A method and apparatus for performing a radiation scan of a structure involve arranging a source of penetrating radiation and a radiation detector at opposed ends of a radiation path through the structure, oriented in such a way that the source emits radiation along the path through the structure and the detector is capable of detecting the radiation after it has passed through the structure and monitoring the radiation emitted from the source that is detected by the detector. At least one continuous loop of a cable is mounted on the structure between at least two fixed locations on the structure so that the cable is movable along its length relative to the structure, and the at least one of the source of penetrating radiation and the radiation detector are fixed to the cable.

Abstract: A digital paper-enabled product includes digital paper with a digital pattern that spatially cooperates with one or more features or boundaries printed on the pattern. More specifically, a system cooperating with the product may include spatial information systems that manage the features or boundaries and communicates with a writing instrument that was used to effect changes to the digital paper-enabled product. In one embodiment, the digital paper-enabled product may take the form of a sheet of digital paper bearing a digital pattern and where action icons (e.g. user intended actions) and/or features (e.g. such as map features) or a spatial reference frame are printed onto the digital pattern and where at least one action palette is printed onto the digital pattern, correlated therewith, and usable to effect changes to the product.

Abstract: Methods and systems for multimedia object association to digital paper spatial diagrams are disclosed herein. A method for multimedia object association to digital paper spatial diagrams includes the steps of (1) capturing a media object to be imported into a spatial information system; (2) linking the captured media object to a digital paper document containing a spatial diagram, using a input device configured to select a linking action area located in a first area of the digital paper document and configured to select a location for the captured multimedia data object on a second area of the digital paper document; (3) transferring the media object and the data from the input device to a spatial information system; and (4) combining the media object and the data of the input device to create an updated digital paper document containing the media object.

Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

Abstract: A method and apparatus are provided for performing a virtual network connection merge. In one example, the method assembles at least one data unit from data traffic of at least one network connection. A credit is calculated for each network connection. A chosen data unit to be transmitted to an output channel is determined based on the credits of the network connections. The chosen data unit is then transmitted to the output channel.

Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: wherein A1, A2, TmR1, X, R2, R3, R9, R12, and R13 are as described in the specification. The compounds are especially useful as inhibitors of ERK2, Aurora2, GSK3, CDK2, AKT3, and ROCK protein kinases and for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, neurodegenerative disorders, inflammatory disorders, restenosis, diabetes, and cardiovascular disease.

Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: wherein A1, A2, TmR1, X, R2, R3, R9, R12, and R13 are as described in the specification. The compounds are especially useful as inhibitors of ERK2, Aurora2, GSK3, CDK2, AKT3, and ROCK protein kinases and for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, neurodegenerative disorders, inflammatory disorders, restenosis, diabetes, and cardiovascular disease.

Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: where B, R1, n, R3, Q, and R4 are described in the specification. The compounds are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.

Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: wherein B, R1, n, R3, Q and R4 are described in the specification. The compounds are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.

Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: wherein A1, A2, TmR1, X, R2, R3, R9, R12, and R13 are as described in the specification. The compounds are especially useful as inhibitors of ERK2, Aurora2, GSK3, CDK2, AKT3, and ROCK protein kinases and for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, neurodegenerative disorders, inflammatory disorders, restenosis, diabetes, and cardiovascular disease.